Abbott, OncoDetect, Molecular Residual Disease, MRD Testing, Whole-Genome Sequencing, Cancer Diagnostics, Precision Oncology, Circulating Tumor DNA, ctDNA, Cancer Recurrence

Abbott Park, Illinois, U.S., October 26, 2026 Abbott has announced the commercial availability of its next-generation OncoDetect® molecular residual...